Gene & Cell Therapy Testing

13 05, 2024

American Assoc. of Pharmaceutical Scientists (AAPS) National Biotechnology Conference – 2024

2025-03-14T18:59:26+00:00

Avance Biosciences™ offers top-tier GLP & GMP compliant services in assay development, validation, & sample testing for biopharma. Visit our booth to explore how we support drug discovery, development, & manufacturing with precision & expertise. [...]

American Assoc. of Pharmaceutical Scientists (AAPS) National Biotechnology Conference – 20242025-03-14T18:59:26+00:00
7 05, 2024

American Society of Gene and Cell Therapy (ASGCT) Conference – 2024

2025-03-14T19:17:52+00:00

Avance Biosciences™ is excited to announce our participation in the American Society of Gene & Cell Therapy (ASGCT) conference, where we’ll be showcasing our advanced services and expertise to propel the future of gene and cell therapy. [...]

American Society of Gene and Cell Therapy (ASGCT) Conference – 20242025-03-14T19:17:52+00:00
6 05, 2024

Workshops on Recent Issues in Bioanalysis (WRIB) Conference – 2024

2025-03-14T19:20:41+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Workshops on Recent Issues in Bioanalysis (WRIB) Conference – 20242025-03-14T19:20:41+00:00
3 04, 2024

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy

2024-07-13T13:07:32+00:00

CAR T-cell therapies show promise for blood cancers but struggle with solid tumors due to T-cell weakness in tumor microenvironments. Researchers find genetic alterations in cancerous T cells, giving engineered T cells "superpowers" to effectively kill tumors without behaving like cancer cells...

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy2024-07-13T13:07:32+00:00
25 03, 2024

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

2024-07-10T19:42:20+00:00

In a groundbreaking development that could revolutionize organ transplantation, eGenesis, a biotechnology company dedicated to addressing the global organ shortage crisis, has announced the successful transplantation of a genetically engineered porcine kidney into a living human recipient...

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient2024-07-10T19:42:20+00:00
10 03, 2024

Society of Toxicology (SOT) Annual Meeting – 2024

2025-03-14T19:25:27+00:00

We are thrilled to announce that Avance Biosciences™ will be attending the highly anticipated Society of Toxicology Annual Meeting in Salt Lake City, and we cordially invite you to join us! More than 5,000 toxicologists and those working in areas related to toxicology will share the latest science and technology...

Society of Toxicology (SOT) Annual Meeting – 20242025-03-14T19:25:27+00:00
6 02, 2024

FDA issues final guidelines on incorporating human genome editing in gene therapy products

2024-07-10T19:46:03+00:00

The guidance provides recommendations regarding information that should be provided in an investigational new drug (IND) application to assess the safety and quality of the investigational GE product, including information on product design, product manufacturing and testing, nonclinical safety...

FDA issues final guidelines on incorporating human genome editing in gene therapy products2024-07-10T19:46:03+00:00
16 01, 2024

FDA’s Innovative Approach to Global Gene Therapy Collaboration

2024-07-16T19:36:13+00:00

In a landmark move, the FDA has initiated the Collaboration on Gene Therapies Global Pilot (CoGenT), signaling a significant leap toward worldwide collaboration in the field of gene therapy. This pilot aims to enable concurrent collaborative reviews of new gene therapy applications with global regulators…

FDA’s Innovative Approach to Global Gene Therapy Collaboration2024-07-16T19:36:13+00:00
Go to Top